# Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
Canonical URL: https://biopharmsignal.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-third-quarter-2025
Ticker: LYEL
Company: Lyell Immunopharma
Source: Lyell Immunopharma
Published: 2025-11-12 21:06 EST
Original Source URL: https://ir.lyell.com
## Summary

Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate that has demonstrated a 67% overall response rate, an 83% disease control rate and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal

## Article Body
Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate that has demonstrated a 67% overall response rate, an 83% disease control rate and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal
## Recent Company News
- 2026-06-01 12:00 EST — [Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-goldman-sachs-47th-annual-global-healthcare-conference-2026) — Source: Lyell Immunopharma
- 2026-05-12 12:00 EST — [Lyell Immunopharma Announces Participation in May Investor Conferences](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-may-investor-conferences) — Source: Lyell Immunopharma
- 2026-05-06 20:05 EST — [Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-first-quarter-2026) — Source: Lyell Immunopharma
- 2026-04-07 12:00 EST — [Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-25th-annual-needham-virtual-healthcare-conference) — Source: Lyell Immunopharma
- 2026-03-12 20:05 EST — [Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-reports-q4-and-full-year-2025-business-and-financial-results) — Source: Lyell Immunopharma
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)